| Literature DB >> 30019928 |
Pavol Zubor1,2, Peter Kubatka2,3, Zuzana Dankova2, Alexandra Gondova1, Karol Kajo4,5, Jozef Hatok6, Marek Samec1,2, Marianna Jagelkova1,2, Stefan Krivus1, Veronika Holubekova2, Jan Bujnak7,8, Zuzana Laucekova1, Katarina Zelinova1,2, Igor Stastny1,2, Marcela Nachajova1, Jan Danko1, Olga Golubnitschaja9,10,11.
Abstract
Metastatic breast cancer is characterized by aggressive spreading to distant organs. Despite huge multilevel research, there are still several important challenges that have to be clarified in the management of this disease. Therefore, recent investigations have implemented a modern, multiomic approach with the aim of identifying specific biomarkers for not only early detection but also to predict treatment responses and metastatic spread. Specific attention is paid to short miRNAs, which regulate gene expression at the post-transcriptional level. Aberrant miRNA expression could initiate cancer development, cell proliferation, invasion, migration, metastatic spread or drug resistance. An miRNA signature is, therefore, believed to be a promising biomarker and prediction tool that could be utilized in all phases of carcinogenesis. This article offers comprehensive information about miRNA profiles useful for diagnostic and treatment purposes that may sufficiently advance breast cancer management and improve individual outcomes in the near future.Entities:
Keywords: individual outcome; metastasis; miRNA; personalized medicine; prediction; prevention; breast cancer
Mesh:
Substances:
Year: 2018 PMID: 30019928 DOI: 10.2217/fon-2018-0061
Source DB: PubMed Journal: Future Oncol ISSN: 1479-6694 Impact factor: 3.404